Cargando…
Trastuzumab emtansine: mechanisms of action and drug resistance
Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate that is effective and generally well tolerated when administered as a single agent to treat advanced breast cancer. Efficacy has now been demonstrated in randomized trials as first line, second line, and later than the second line treatment...
Autores principales: | Barok, Mark, Joensuu, Heikki, Isola, Jorma |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4058749/ https://www.ncbi.nlm.nih.gov/pubmed/24887180 http://dx.doi.org/10.1186/bcr3621 |
Ejemplares similares
-
Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation
por: Barok, Mark, et al.
Publicado: (2018) -
Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo
por: Barok, Mark, et al.
Publicado: (2011) -
Extracellular vesicles as modifiers of antibody‐drug conjugate efficacy
por: Barok, Mark, et al.
Publicado: (2021) -
Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
por: Hunter, Francis W., et al.
Publicado: (2019) -
Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer
por: Oostra, Drew R, et al.
Publicado: (2014)